Prasinezumab
- Generic Name
- Prasinezumab
- Drug Type
- Biotech
- CAS Number
- 1960462-19-4
- Unique Ingredient Identifier
- P3Z0Z3P1ZI
- Background
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- Conditions
- Parkinsons Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 586
- Registration Number
- NCT04777331
- Locations
- ๐บ๐ธ
Dent Neurological Institute, Amherst, New York, United States
๐ฎ๐นA.O.U. Policlinico "G.Rodolico - San Marco", Catania, Sicilia, Italy
๐ฎ๐นA.O. Universitaria Pisana, Pisa, Toscana, Italy
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT03100149
- Locations
- ๐บ๐ธ
Barrow Neurology Clinics, Phoenix, Arizona, United States
๐บ๐ธAventura Neurologic Associates, Aventura, Florida, United States
๐บ๐ธUniversity of Vermont Medical Center, Burlington, Vermont, United States
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Prothena Biosciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT02157714
- Locations
- ๐บ๐ธ
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
๐บ๐ธCollaborative Neuroscience Network, LLC, Long Beach, California, United States
๐บ๐ธParkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
Single Ascending Dose Study of PRX002 in Healthy Subjects
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Prothena Biosciences Limited
- Target Recruit Count
- 40
- Registration Number
- NCT02095171
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.